Clarkston Capital Partners LLC Has $1.50 Million Holdings in Pfizer Inc. (NYSE:PFE)

Clarkston Capital Partners LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,688 shares of the biopharmaceutical company’s stock after selling 1,089 shares during the period. Clarkston Capital Partners LLC’s holdings in Pfizer were worth $1,504,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of PFE. United Bank raised its holdings in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Pfizer by 0.5% during the third quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock worth $15,348,000 after purchasing an additional 2,600 shares in the last quarter. Kovitz Investment Group Partners LLC grew its stake in shares of Pfizer by 35.4% during the third quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock valued at $10,612,000 after purchasing an additional 95,896 shares during the last quarter. Hendershot Investments Inc. increased its holdings in shares of Pfizer by 12.7% in the third quarter. Hendershot Investments Inc. now owns 24,895 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 2,798 shares in the last quarter. Finally, DF Dent & Co. Inc. raised its position in Pfizer by 11.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock worth $1,323,000 after purchasing an additional 4,852 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on PFE. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Down 5.4 %

Shares of Pfizer stock opened at $22.99 on Friday. Pfizer Inc. has a 1 year low of $22.95 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business has a 50-day moving average of $25.87 and a two-hundred day moving average of $26.74.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.